ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 64 citations in OpenAlex.
- Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.Blood · 2019Trial
- An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.Clinical lymphoma, myeloma & leukemia · 2018Trial
- Roles of Uridine Diphosphoglucuronosyltransferase 2B Enzymes in Cancer Susceptibility and Treatment: A Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- CD40L and IL-4 lymph node-associated signals protect B cells from rituximab-induced ADCC via KIR and NKG2A.Clinical and experimental immunology · 2026Article
- High-content imaging of primary chronic lymphocytic leukemia cells predicts patient cohorts with distinct cellular drug responses.iScience · 2025Article
- Heme oxygenase 1 confers gilteritinib resistance in FLT3-ITD acute myeloid leukemia in a STAT6-dependent manner.Cancer cell international · 2025Article
- CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis.Immunotherapy advances · 2025Article
- Screening and identification of host signaling pathways for alleviating influenza-induced production of pro-inflammatory cytokines, IP-10, IL-8, and MCP-1, using a U937 cell-based influenza model.Frontiers in microbiology · 2025Article
- Discovery of novel 2,4-diarylaminopyrimidine hydrazone derivatives as potent anti-thyroid cancer agents capable of inhibiting FAK.Journal of enzyme inhibition and medicinal chemistry · 2024Article
- Identification of novel PAD2 inhibitors using pharmacophore-based virtual screening, molecular docking, and MD simulation studies.Scientific reports · 2024Article
- Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity.Journal of medicinal chemistry · 2024Article
- Targeting TYK2 alleviates Rab27A-induced malignant progression of non-small cell lung cancer via disrupting IFNα-TYK2-STAT-HSPA5 axis.NPJ precision oncology · 2024Article
- B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia.Frontiers in oncology · 2024Review
- Article
- Heterogeneity of Patient-Derived Acute Myeloid Leukemia Cells Subjected to SYK In Vitro Inhibition.International journal of molecular sciences · 2022Article
- Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies.Leukemia & lymphoma · 2022Review
- A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas.Haematologica · 2022Article
- In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing.Cancers · 2022Review
- Review
- Inhibitors Targeting Multiple Janus Kinases FromFrontiers in chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 2 countries.
Matthew D BluntCancer Sciences Unit (MP824), University of Southampton, Southampton, United Kingdom.
Stefan KoehrerDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Rachel C DobsonCancer Sciences Unit (MP824), University of Southampton, Southampton, United Kingdom.
Marta LarrayozCancer Sciences Unit (MP824), University of Southampton, Southampton, United Kingdom.
Sarah WilmoreCancer Sciences Unit (MP824), University of Southampton, Southampton, United Kingdom.
Alice HaymanCancer Sciences Unit (MP824), University of Southampton, Southampton, United Kingdom.
Jack ParnellCancer Sciences Unit (MP824), University of Southampton, Southampton, United Kingdom.
Lindsay D SmithCancer Sciences Unit (MP824), University of Southampton, Southampton, United Kingdom.
Andrew DaviesCancer Sciences Unit (MP824), University of Southampton, Southampton, United Kingdom.
Peter W M JohnsonCancer Sciences Unit (MP824), University of Southampton, Southampton, United Kingdom.
Pamela B ConleyPortola Pharmaceuticals, South San Francisco, California.
Anjali PandeyPortola Pharmaceuticals, South San Francisco, California.
Jonathan C StreffordCancer Sciences Unit (MP824), University of Southampton, Southampton, United Kingdom.
Freda K StevensonCancer Sciences Unit (MP824), University of Southampton, Southampton, United Kingdom.
Graham PackhamCancer Sciences Unit (MP824), University of Southampton, Southampton, United Kingdom.
Francesco ForconiCancer Sciences Unit (MP824), University of Southampton, Southampton, United Kingdom.
Greg P CoffeyPortola Pharmaceuticals, South San Francisco, California.
Jan A BurgerDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Andrew J SteeleCancer Sciences Unit (MP824), University of Southampton, Southampton, United Kingdom. A.Steele@soton.ac.uk.
University of Southampton · GBSunesis (United States) · USThe University of Texas MD Anderson Cancer Center · USUniversity Hospital Southampton NHS Foundation Trust · GB
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MCancer Research UK 23669Cancer Research UK A15581Cancer Research UK A18087NCI NIH HHS P30 CA016672
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdenineAntineoplastic Combined Chemotherapy ProtocolsApoptosisB-LymphocytesBridged Bicyclo Compounds, HeterocyclicFlow CytometryGene Expression Regulation, NeoplasticHumansJanus Kinase InhibitorsJanus KinasesLeukemia, Lymphocytic, Chronic, B-CellLeukocytes, MononuclearNeoplasm ProteinsPiperidinesProto-Oncogene Proteins c-bcrPyrazoles4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamideAdenineBCR protein, humanBridged Bicyclo Compounds, HeterocyclicibrutinibJanus Kinase InhibitorsJanus KinasesNeoplasm ProteinsPiperidinesProto-Oncogene Proteins c-bcrPyrazolesPyrimidinesReceptors, Antigen, B-CellSulfonamidesSulfonesSyk KinaseSYK protein, humanvenetoclax
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.